Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Cholinesterase inhibitor use does not significantly influence the ability of I-123-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies

Lookup NU author(s): Professor John-Paul TaylorORCiD, Dr Sean CollobyORCiD, Professor Ian McKeith, Professor David BurnORCiD, Dr David Williams, Professor John O'Brien

Downloads


Abstract

Background: I-123- labelled 2 beta- carbomethoxy- 3 beta-( 4- iodophenyl)- N-( 3- fluoropropyl) nortropane ( I-123- FP- CIT) imaging is a diagnostic tool to help differentiate dementia with Lewy bodies ( DLB) from Alzheimer's disease ( AD). However, in animals, cholinesterase inhibitors ( ChEi) have been reported to reduce radioligand binding to the striatal dopamine transporter. As ChEi are frequently used in people with dementia, it is important to determine whether their use affects I-123- FP- CIT uptake in the striatum. Objective: To clarify whether chronic ChEi therapy modulates striatal dopamine transporter binding measured by I-123- FP- CIT in patients with AD, DLB and Parkinson's disease with dementia ( PDD). Design: Cross sectional study in 99 patients with AD ( nine on ChEi, 25 not on ChEi), DLB ( nine on ChEi, 19 not on ChEi) and PDD ( six on ChEi, 31 not on ChEi) comparing I-123- FP- CIT striatal binding ( caudate, anterior and posterior putamen) in patients receiving compared with those not receiving ChEi, correcting for key clinical variables including diagnosis, age, sex, Mini- Mental State Examination score, severity of parkinsonism and concurrent antidepressant use. Results: As previously described, I-123- FP- CIT striatal uptake was lower in DLB and PDD subjects compared with those with AD. Median duration of ChEi use was 180 days. I-123- FP- CIT uptake was not significantly reduced in subjects receiving ChEi compared those not receiving ChEi ( mean percentage reduction: AD 4.3%; DLB 0.7%; PDD 6.1%; p = 0.40). ChEi use did not differentially affect striatal (FP)-F-123- CIT uptake between patient groups ( p = 0.83). Conclusions: Use of ChEi does not significantly influence the ability of 123I- FP- CIT imaging to distinguish AD from DLB.


Publication metadata

Author(s): Taylor JP, Colloby SJ, McKeith IG, Burn DJ, Williams D, Patterson J, O'Brien JT

Publication type: Article

Publication status: Published

Journal: Journal of Neurology, Neurosurgery and Psychiatry

Year: 2007

Volume: 78

Issue: 10

Pages: 1069-1071

Date deposited: 21/06/2010

ISSN (print): 0022-3050

ISSN (electronic): 1468-330X

Publisher: BMJ Group

URL: http://dx.doi.org/10.1136/jnnp.2006.111666

DOI: 10.1136/jnnp.2006.111666


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
G0400074Medical Research Council
G0502157Medical Research Council

Share